Blay, Jean-Yves

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 1,764

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 1,384

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology

Sarcoma Diagnosis and TreatmentCardiac tumors and thrombi

Cited by 1,115

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome

Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 758

Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.

Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 617

Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor

Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y. (1998) · Blood

Immunotherapy and Immune ResponsesImmune cells in cancer

Cited by 590

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 571

Deep learning-based classification of mesothelioma improves prediction of patient outcome

Courtiol, P., Maussion, C., Moarii, M., Pronier, E., Pilcer, S., Sefta, M., Manceron, P., Toldo, S., Zaslavskiy, M., Le Stang, N., et al. (2019) · Nature Medicine

AI in cancer detectionOccupational and environmental lung diseases

Cited by 544

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 513

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., et al. (2023) · Nature Medicine

Melanoma and MAPK PathwaysGastrointestinal Tumor Research and Treatment

Cited by 343

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 331

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E., Chevreau, C., Duffaud, F., Entz-Werlé, N., Saada, E., et al. (2020) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentCancer Cells and Metastasis

Cited by 326

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation

Gastrointestinal Tumor Research and TreatmentImmune Cell Function and Interaction

Cited by 302

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 245

Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research

Gastrointestinal Tumor Research and TreatmentMast cells and histamine

Cited by 202

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., et al. (2019) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 174

Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells

Faget, J., Biota, C., Bachelot, T., Gobert, M., Treilleux, I., Goutagny, N., Durand, I., Léon-Goddard, S., Blay, J. Y., Caux, C., et al. (2011) · Cancer Research

Chemokine receptors and signalingImmune cells in cancer

Cited by 129

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., et al. (2020) · Investigational New Drugs

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 127

MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer

Cipponi, A., Goode, D. L., Bedo, J., McCabe, M. J., Pajic, M., Croucher, D. R., Rajal, A. G., Junankar, S. R., Saunders, D. N., Lobachevsky, P., et al. (2020) · Science

PI3K/AKT/mTOR signaling in cancerEvolution and Genetic Dynamics

Cited by 103

Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study

Duffaud, F., Italiano, A., Bompas, E., Rios, M., Penel, N., Mir, O., Piperno-Neumann, S., Chevreau, C., Delcambre, C., Bertucci, F., et al. (2021) · European Journal of Cancer

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and Treatment

Cited by 52

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)

Penel-Page, M., Ray-Coquard, I., Larcade, J., Girodet, M., Bouclier, L., Rogasik, M., Corradini, N., Entz-Werle, N., Brugieres, L., Domont, J., et al. (2015) · BMC Cancer

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 32